Exosomal MicroRNA Expression in Children With Autism Spectrum Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is accumulating evidence that genetic expression plays a role in autism spectrum disorder, but the regulation of such genes is poorly understood. Small RNA particles, called microRNA (miRNA), have the ability to alter gene expression. These particles can be packaged and released from brain cells into the blood. Changes in miRNA may contribute to the patterns observed in autism spectrum disorder.

The purpose of this study is to identify small RNA particles that regulate gene expression in autism spectrum disorder. The goal is to identify miRNA expression patterns which may improve our understanding and diagnosis of autism spectrum disorder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will recruit 20 children with idiopathic ASD (defined by DSM-IV criteria) and 20 age- and gender-matched controls with typical neuropsychological developmental patterns. The number of subjects necessary for this study was determined by power analysis. Using a two sample t-test model with 15 ASD and 15 control subjects in each group would have 80% power to detect changes in expression equal to twice the standard deviation of the group mean with Bonferonni corrected level (p\<0.0001) based on expectations of measuring 500 miRNA in each sample (Lenth, 2006).

Parental consent and patient assent forms will be distributed to potential subjects at the University Pediatric and Adolescent Center and the Center for Development Behavior and Genetics. To explain the study, children will be told, "The doctors are doing a study about a disease called autism. If you want to be in this study a small amount of blood will be taken from your arm with a needle. The needle will hurt but will go away after a little while. The doctors will ask you to answer some questions about how you feel. You do not have to be in the study. No one will be mad at you if you don't want to do this."

ASD subjects will be assessed using current methods in autism diagnosis: the Autism Diagnostic Observation Schedule (ADOS) and the Checklist for Autism in Toddlers (CHAT). The Vineland Behavior Scales will also be administered. All medical information collected will be coded and de-identified according to standard protocols.

Venipuncture will be employed to collect 2ml of blood from each subject into an EDTA-free vacutainer tube. Samples will be left for 1 hour at 37˚C to allow clotting before storage at 4˚C overnight. The sample will then be centrifuged at 4000 rpm for 20 minutes at 4˚C. Serum will be removed from the clot by pipetting and stored at -80˚C until miRNA extraction is performed.

The decision to measure exosomal miRNA from serum is supported by a study of miRNA in 12 human body fluids. Weber and colleagues (2010) determined that the median total concentration of RNA in plasma (308 ug/L) was greater than that of cerebrospinal fluid (111 ug/L). Furthermore, the authors found the number of detectable miRNAs in plasma (349) to be greater than cerebrospinal fluid (212). The miRNA content of plasma and cerebrospinal fluid has some intriguing similarities. Of the twenty most abundant miRNAs found in cerebrospinal fluid and plasma, 9 overlap. We have previously examined the expression of exosomal miRNA in the serum of human alcoholic subjects. Intriguingly, we characterized the expression levels of brain-specific miRNAs in serum samples from over 30% of those tested. This finding demonstrates that exosomal miRNAs from the central nervous system can be detected and quantified in human blood samples.

Serum miRNA will be extracted using a Qiagen RNeasy Mini Kit according to manufacturer protocol. RNA will be processed with the Genisphere FlashTag HSR RNA labeling kit. RNA Spike Control Oligos, and poly(A) tails will be added to each RNA sample and a biotinylated signaling molecule will be ligated to the RNA. The labeled RNA samples will be added to a hybridization cocktail, incubated, and injected into Affymetrix miRNA 2.0 arrays. After 16 hours of hybridization, the arrays will be washed and stained on an Affymetrix fluidics station 450 using protocol FS450\_0003. Arrays will be scanned on an Affymetrix GeneChip Scanner 7G Plus. The cel files will be analyzed using miRNA QC Tool version 1.1.1.0.

A 3-way ANOVA assessing the impact of ASD, age, and gender on miRNA expression will be employed along with a Mann Whitney Test. Targets with a P-value \< 0.05 will be selected for further analysis after multiple testing correction with Bonferroni analysis. Significantly altered miRNAs will be queried on Mirbase.org for known mRNA targets. The target list will then be examined using DAVID bioinformatics functional annotation tool for enriched gene ontology categories. Correlations between miRNA expression and medical/neuropsychological characteristics will be calculated using Pearson Correlation statistics, filtering for miRNAs with p-value\<0.05 and r\>0.5.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Autism

Children ages 4-17 years old with DSM-IV defined autism spectrum disorder

No interventions assigned to this group

Control

Age- and gender-matched controls with typical neuropsychological developmental patterns

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children ages 4-17

Exclusion Criteria

* neurological impairments (i.e. cerebral palsy, epilepsy)
* sensory deficits (i.e. sensory or visual impairments)
* psychological disorders (i.e. obsessive compulsive disorder, attention deficit disorder)
* control subjects with family history of autism spectrum disorder
* mental retardation
* history of preterm birth

Minimum Eligible Age

4 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Steven Hicks, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

SUNY Upstate Medical University, Department of Pediatrics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

SUNY Upstate Medical University

Syracuse, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

346301-1

Identifier Type: -

Identifier Source: org_study_id